ArticleFrontiers in endocrinology2026
Atherogenic index of plasma and the severity of coronary artery stenosis in patients with type 2 diabetes mellitus: a retrospective cross-sectional study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to examine the relationship between the Atherogenic Index of Plasma (AIP) and the severity of coronary artery stenosis in patients with type 2 diabetes mellitus (T2DM). Methods: In this retrospective cross-sectional study, 303 T2DM patients who had not been treated with statins and underwent coronary computed tomography angiography (CCTA) were included. AIP was calculated as log Results: A clear dose-response trend was found between increasing AIP quartiles and greater severity of coronary stenosis (P for trend <0.01). The median AIP was significantly higher in patients with severe stenosis (≥70%) compared to those with non-obstructive disease (0.14 vs. 0.05, P<0.001). After adjusting for multiple variables, AIP remained independently associated with obstructive stenosis (≥50%), with an odds ratio of 3.93 (95% confidence interval: 1.70-9.62). The area under the ROC curve (AUC) for AIP was 0.598 (95% CI: 0.540-0.653), which was significantly better than that for LDL cholesterol (0.481, P = 0.032) and HDL cholesterol (0.384, P<0.001). Conclusion: Higher AIP levels are independently associated with more severe coronary stenosis in patients with T2DM and demonstrate superior discriminative ability compared to traditional lipid markers in this cross-sectional cohort. Therefore, AIP may be considered an adjunctive biomarker for cardiovascular risk stratification in this high-risk population, pending prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.